National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

cefpodoxime proxetil
A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:cefpodoxime
US brand name:Vantin



Previous:CeeNU, cefazolin sodium, cefepime hydrochloride, cefixime, cefotaxime
Next:ceftazidime sodium, ceftobiprole medocaril, Celebrex, celecoxib, Celestone

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov